Sofia

• Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl Ended
  2023-504698-19-00 2 2025-05-30 Bioequivalence trial in healthy volunteers
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended
  2024-515386-34-00 4 2025-05-29 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single … Ended
  2024-513577-43-00 3 2025-05-16 Participants with normal hepatic function
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A comparison study between adolescents with asthma and adults with asthma on how they absorb, metabolise and eliminate CHF 6001 Ended
  2024-516483-29-00 4 2025-03-24 Asthma
• Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotei … Ended
  2024-516475-32-00 3 2025-03-17 Chronic obstructive pulmonary disease
• Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTE … Ended
  2024-517969-16-00 3 2025-03-12 No therapeutic indication in the current trial with healthy volunteers
• Evaluation of the bioequivalence of two products containing esomeprazole under fed conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexi … Ended
  2024-512674-97-00 2 2025-03-11 No therapeutic indication in the current trial with healthy volunteers
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• A proof-of-concept study of lunsekimig compared with placebo in adults with chronic rhinosinusitis with nasal polyps Ended
  2024-511261-11-00 4 2025-03-05 Respiratory tract diseases
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4 … Ended
  2024-516840-24-00 3 2025-03-05 Chronic Kidney disease
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended
  2024-513036-26-00 5 2024-12-20 Bipolar I Disorder (Bipolar Mania)
• A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania Ended
  2024-513037-20-00 5 2024-12-19 Bipolar I Disorder (Bipolar Mania)
• A study to compare two different aramchol formulations in healthy volunteers. Ended
  2023-507445-28-00 3 2024-12-18 Nonalcoholic fatty liver disease
• A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP118 … Ended
  2024-514981-37-00 4 2024-12-05 Rheumatoid Arthritis
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates Ended
  2024-513495-17-00 3 2024-11-20 Dermatitis atopic
• A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants with Renal Impairment Ended
  2024-514359-14-00 3 2024-11-18 Impaired renal function
• Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einne … Ended
  2024-515170-27-00 2 2024-11-15 No therapeutic indication in the current trial with healthy volunteers
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Parti … Ended
  2024-513848-28-00 3 2024-11-11 Healthy Volunteers
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended
  2024-516240-26-00 5 2024-10-11 Influenza

Showing 409–432 of 590 trials